President Trump announced a plan to impose tariffs of up to 100% on imported generic drugs starting in 2028.
President Trump announced a plan to impose tariffs of up to 100% on imported generic drugs beginning in 2028 to encourage manufacturers to move production to the United States. The administration announced that these tariffs will increase to 200% after one year, providing a two-year runway for companies to reshore production. Currently, the U.S. relies heavily on overseas markets, with India supplying over 50% of generic prescriptions and China providing the majority of imported ibuprofen and acetaminophen. While the administration aims to strengthen domestic supply chains, health policy experts expressed skepticism regarding whether tariffs alone will suffice. Experts noted that because generic drug manufacturing requires specific infrastructure and high upfront costs, manufacturers must weigh the potential profits against the expense of building U.S. facilities. While some analysts warn that high costs could lead to supply shortages or higher consumer prices, others suggest that the modest nature of generic drugs may keep price increases manageable. The administration highlighted that this move follows a successful track record of securing reshoring plans for branded drugs.